Semisolid, self-catalyzed poly(ortho ester)s as controlled-release systems: Protein release and protein stability issues

Journal of Pharmaceutical Sciences

Volumn 91, Issue 4, 2002, Pages 1065-1074

  Van Weert, Marco De ^a,c   Van Steenbergen, Marinus J ^a   Cleland, Jeffrey L ^a   Heller, Jorge ^a   Hennink, Wim E ^b   Crommelin, Daan J A ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b GENENTECH INC   (United States)

^c AP Pharma   (United States)

Author keywords

Controlled release; Poly(ortho ester)s; Protein stability; Semisolid

Indexed keywords

ALPHA LACTALBUMIN; BOVINE SERUM ALBUMIN; LYSOZYME; POLY(ORTHO ESTER); POLYMER; SUCROSE; TREHALOSE; VASCULOTROPIN;

ARTICLE; CATALYSIS; CONTROLLED RELEASE FORMULATION; DISSOLUTION; DRUG DEGRADATION; DRUG SOLUBILITY; ISOELECTRIC POINT; KINETICS; PH; PROTEIN AGGREGATION; PROTEIN SECRETION; PROTEIN STABILITY; SUSTAINED RELEASE PREPARATION;

EID: 0036279839     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10109     Document Type: Article

References (36)

1. Protein instability in poly(lactic-co-glycolic acid) microparticles
2. Poly(ortho esters) - Their development and some recent applications
3. Concomitant and controlled release of dexamethasone and 5-fluorouracil from poly(ortho ester)
4. Recent developments in the synthesis and utilization of poly(ortho esters)
5. Studies on micro-encapsulation of 5-fluorouracil with poly(ortho ester) polymers
6. Development of a poly(ortho ester) prototype with a latent acid in the polymer backbone for 5-fluorouracil delivery
7. Bioerodible devices based in poly(ortho esters) for controlled delivery of tetracycline to periodontal pocket
8. Synthesis and erosion studies of self-catalyzed poly(ortho ester)s
9. Erosion characteristics of catalyzed poly(ortho ester) matrices
10. Hydrolysis and erosion studies of autocatalyzed poly(ortho esters) containing lactoyl-lactyl acid dimers
11. The use of poly(ortho esters) in the treatment of cancer and in the pulsed release of proteins
12. Pulsatile and delayed release of lysozyme from ointment-like poly(ortho esters)
13. Local delivery of vascular endothelial growth factor via PLGA depots for treatment of vascular disease
14. Development of poly(D,L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis
15. Measurement of protein using bichinchoninic acid
16. Release of protein from a poly(ortho ester) film during surface erosion studied by in situ atomic force microscopy
17. Kinetic evidence for the formation of acyl-enzyme intermediates in the α-chymotrypsin-catalyzed hydrolysis of specific substrates
18. Adsorption kinetics, conformation, and mobility of growth hormone and lysozyme on solid surfaces studied by TIRF
19. Serum albumin
20. α-Lactalbumin: Structure and function
21. Polymerization of penicillins
22. Improved biocompatibility of a viscous bioerodible poly(ortho ester) by controlling the environmental pH during degradation
23. New insights into the hydrolytic degradation of poly(lactic acid): Participation of the alcohol terminus
24. Infrared spectroscopy studies of lyophilization- and temperature-induced protein aggregation
25. Lysozyme distribution and conformation in a biodegradable polymer matrix as determined by FTIR techniques
26. Fourier transform infrared spectroscopic analysis of protein conformation: Effect of sampling method and stress factors
27. The effect of a water/organic solvent interface on the structural stability of lysozyme
28. Moisture-induced aggregation of lyophilized proteins in the solid state
29. Solid-phase aggregation of proteins under pharmaceutical relevant conditions
30. Rational design of lyophilized protein formulations: Some practical advice
31. Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone
32. Secondary structure of proteins in the amorphous dehydrated state probed by FTIR spectroscopy. Dehydration-induced structural changes and their prevention
33. Use of lyoprotectants in the freeze-drying of a model protein, ribonuclease A
34. Lyophilization and development of solid protein pharmaceuticals
35. The influence of sucrose, dextran, and hydroxypropyl-beta-cyclo-dextrin as lyoprotectants for a freeze-dried mouse IgG2a monoclonal antibody (MN12)
36. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency